#United States #New York #Class Action #Bronstein Gewirtz #Jasper Therapeutics

Investor Alert: Join the Action Against Jasper Therapeutics

Overview

Recent news has emerged that Jasper Therapeutics, Inc. is facing a significant class action lawsuit, which provides an opportunity for investors who have incurred substantial losses. This legal action, led by the prominent law firm Bronstein, Gewirtz & Grossman LLC, aims to rectify alleged violations of federal securities laws by the company and certain of its officers. As an impacted investor, it's crucial to understand the details regarding this lawsuit and your potential involvement.

Background on Jasper Therapeutics

Jasper Therapeutics is a biopharmaceutical company focused on developing advanced therapies for patients with serious diseases. However, the company's recent operational practices have raised concerns. The lawsuit alleges that during the class period, from November 30, 2023, to July 3, 2025, Jasper made misleading assertions and failed to disclose critical information regarding its manufacturing processes and compliance with current Good Manufacturing Practice (cGMP) regulations.

The Allegations

According to the filed complaint, several key allegations have surfaced:
1. Lack of Proper Controls: Jasper allegedly did not have adequate controls and procedures to ensure that third-party manufacturers followed cGMP regulations, resulting in potential product quality issues.
2. Risk of Confounded Studies: This deficiency increased the risk that ongoing clinical studies could yield unreliable results, negatively affecting the regulatory and commercial prospects for products like briquilimab.
3. Increased Likelihood of Cost-Cutting: The lawsuit suggests that these oversights could lead Jasper to implement disruptive cost-reduction measures, jeopardizing its financial stability.
4. Overstated Business Prospects: Consequently, the lawsuit claims that Jasper's public statements regarding its business and financial outlook were false and misleading, presenting a rosier picture than reality.

Next Steps for Investors

For those who have invested in Jasper's securities within the specified class period, this is a pivotal moment. The lawsuit is already underway, and affected individuals are encouraged to consider joining the case. To take action:

• - Visit Bronstein Gewirtz & Grossman's website for detailed information on the lawsuit and how to participate.
• - If you suffered financial losses as a result of your investment in Jasper, you have until November 18, 2025, to formally request to be appointed as lead plaintiff in this case.

Important Considerations

Participating in this class action lawsuit entails no upfront costs for you. The law firm operates on a contingency fee basis, which means they only get reimbursed for their expenses and fees should they succeed in winning the case. This structure allows investors to seek justice without financial risk.

Why Choose Bronstein, Gewirtz & Grossman?

With a track record of recovering hundreds of millions of dollars for investors across various cases, Bronstein, Gewirtz & Grossman is well-equipped to handle such complex securities fraud matters. They offer a dedicated team ready to support investors through every step of the legal process.

Stay Informed

If you are interested in updates regarding this lawsuit or additional investor alerts, you can follow Bronstein, Gewirtz & Grossman on LinkedIn, Twitter, Facebook, or Instagram. Now is the time to explore your options and safeguard your investments.

Conclusion

Don't let your losses go unaddressed. If you believe you have been affected by the alleged actions of Jasper Therapeutics, it's crucial to act promptly. Engage with legal experts to understand your rights and possible next steps in this important financial matter.